Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vimian Group AB ( (SE:VIMIAN) ) is now available.
Vimian Group AB has announced that it will publish its year-end report for 2025 on Thursday 12 February at 07:45 CET, followed by an English-language audiocast for investors, analysts and media at 09:00 CET, where CEO Alireza Tajbakhsh and CFO Carl-Johan Zetterberg Boudrie will present and comment on the results and take questions. The company is providing both telephone and webcast access, with presentation materials to be made available on its website in advance, underscoring its efforts to maintain transparent communication with the market and engage stakeholders around its financial performance and strategic development in the global animal health sector.
The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK30.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB is a global animal health company operating across four key segments: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, Sweden, it serves more than 17,000 veterinary clinics and laboratories in over 80 markets, employs around 1,200 people and generates annual revenues of approximately EUR 375 million, focusing on making innovative animal health solutions widely accessible to veterinary professionals and pet owners.
YTD Price Performance: -12.00%
Average Trading Volume: 251,102
Technical Sentiment Signal: Sell
Current Market Cap: SEK14.04B
For detailed information about VIMIAN stock, go to TipRanks’ Stock Analysis page.